New Approach Methodologies in Oncology: From Concept to Use
In this CrownCast episode, host Michelle Dawn Mooney speaks with Graham Marsh, Director of the NAMs Developer Coalition at the Critical Path Institute, and Ludovic Bourré, Vice President of Research and Innovation at Crown Bioscience, to explore new approach methodologies (NAMs) and Crown Bioscience’s participation in the coalition. Together, they discuss how patient-derived models, organoids, ex vivo tissue platforms, translational biomarkers, and bioinformatics contribute to the field, and what validation, qualification, and regulatory adoption could mean for practical study design.
23 Sept 2026
Syngeneic vs. Humanized Models: How to Choose the Right Model for Immuno-Oncology Research
Choosing the right preclinical immuno-oncology model makes or breaks your development decisions, but navigating the options is rarely simple.
In this CrownCast episode, host Michelle Dawn Mooney sits down with Chris Dillon, Executive Director of In Vivo at Crown Bioscience's San Diego site, to explore how syngeneic tumor models support preclinical immunotherapy research and how model selection, engineering, and translational relevance come together to build studies that deliver actionable results.
29 May 2026
Top Cancer Research Trends and Innovations Identified by Experts
At AACR 2026, one message became clear: oncology drug development is entering a new era defined by smarter decision-making, integrated platforms, and increasingly precise therapeutic strategies. In this CrownCast episode, Crown Bioscience experts shared their perspectives from the conference, highlighting the technologies, modalities, and translational approaches that are poised to shape the future of cancer research.
From AI-enabled target discovery to spatial biology and next-generation therapeutic modalities, the discussions reflected a rapidly evolving ecosystem where innovation is no longer incremental. Instead, the industry is moving toward highly integrated workflows designed to accelerate development timelines, reduce risk, and improve patient outcomes.
26 Mar 2026
Mastering Radiopharmaceutical Development - Preclinical Model Selection for Clinical Success
What if the next breakthrough in cancer treatment isn't a pill or infusion, but a precisely targeted radioactive payload that hunts down tumor cells like a guided missile? In this Smart Biotech Scientist Podcast episode, Dr. David Brühlmann speaks with Bryan Miller, Director of Scientific and Technical Operations at Crown Bioscience UK, about the radiopharmaceutical revolution transforming oncology. From theranostic approaches to advanced preclinical modeling, Miller shares insights on how this emerging therapeutic class is reshaping cancer treatment strategies.
19 Mar 2026
Beyond Efficacy: Why DMPK and Toxicology Matter Earlier Than You Think
When people hear Crown Bioscience, they often think of world-class in vivo oncology models - and for good reason. But behind every successful oncology program is something just as critical: understanding how a drug behaves in the body and whether it can do so safely.
In this CrownCast episode, host Michelle Dawn Mooney sits down with Rekha Pal, Senior Director of Scientific Engagement, and Santi Suryani Chen, Director of Business Development at Crown Bioscience, to explore where DMPK and toxicology fit into the drug discovery picture and how getting them right can save programs from costly detours.
25 Feb 2026
ADC Development Revolution - Leveraging Translational Models for Next-Generation Cancer Therapeutics
8 Jan 2026
CrownCast - The Radiopharmaceutical Revolution Driving Precision in Treatment
11 Nov 2025
Transforming Cancer Drug Development in the UK: Perspectives and Breakthroughs
Across the global oncology drug discovery landscape, the UK stands at the forefront. In this CrownCast episode, Rajendra Kumari, Executive Director of Integrated Solutions at Crown Bioscience, talks with Sarah Wagner, Senior Director of Business Development and Bryan Miller, Director of Scientific and Technical Operations about leveraging the UK’s vibrant ecosystem of cutting-edge technologies, strong collaborations, and a commitment to high ethical standards.
30 Oct 2025
Harnessing the Power of High-quality Biospecimens
As cancer research progresses rapidly, obtaining high-quality biospecimens has grown increasingly important for making significant breakthroughs.
In this CrownCast episode, Rajendra Kumari, Executive Director of Integrated Solutions at Crown Bioscience, talks with Sadaf Malik, Senior Director, Head US Sales (Biobank and Biomarker) about how superior biospecimens can drive advancements in oncology by means of innovative biobanking.
5 Aug 2025
The Future of Drug Development: How Organoids Are Leading the Charge
As the landscape of drug discovery evolves, breakthrough technologies like organoids are gaining traction for their potential to revolutionize how new treatments are developed. In this episode of CrownCast, Jonny McMichael, Vice President at Crown Bioscience, and Leo Price, a member of Crown Bioscience’s Scientific Advisory Board, shed light on organoids' growing role in drug development. With insights into their application, this commentary delves into a technology that offers a significant leap toward personalized medicine, ushering in a new era for the healthcare industry.
27 Jun 2025
Navigating the Future of Preclinical Testing Post-FDA Animal Testing Mandate
This episode explores modern technologies that move beyond animal testing in drug discovery, promising a more efficient future for pharmaceutical companies and patients.
16 May 2025
Evolving Biomarkers: Charting the Future of Precision Medicine
In a rapidly shifting landscape of personalized medicine, biomarkers have become central to shaping the way drug development and clinical trials unfold. From predicting therapeutic response to identifying optimal patient populations, the complexity and scope of biomarker use has increased alongside technological advances. A key success story like the BCR-ABL biomarker in chronic myeloid leukemia demonstrates the power of targeted medicine, which has raised five-year survival rates from around 30–50% to over 90%. With the rise of multi-omics and AI-driven analytics, the industry is entering a new era of integration, data complexity—and unprecedented possibility.
6 May 2025
Pioneering Strategies to Unlocking the Potential of KRAS
Once labeled “undruggable,” KRAS has emerged as one of oncology’s most promising—yet complex—targets. With nearly 90% of pancreatic cancers and 30-40% of lung and colorectal cancers harboring KRAS mutations, the need for effective therapies is urgent. Recent FDA approvals of KRAS G12C inhibitors have signaled a new era, but the rise of resistance and diverse mutation profiles demand deeper innovation. As preclinical tools and combination strategies evolve, scientists must ask: how do we stay ahead of KRAS-driven resistance and translate insights into patient-specific treatment success?
19 Apr 2025
Inside Oncology Drug Development: Overcoming Resistance with Science
In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that resistance often leads to disease relapse, severely impacting patient outcomes and quality of life.
26 Mar 2025
Exploring Artificial Intelligence in Drug Discovery
Artificial intelligence is rapidly reshaping the drug discovery process, moving from augmenting research to actively driving innovation. As biotech companies face soaring R&D costs and long development cycles, AI promises a breakthrough: slashing drug development time by nearly half while improving accuracy in identifying promising compounds. With global pharmaceutical R&D spending projected to exceed $230 billion by 2026, efficiency isn't just desirable—it's critical.
25 Mar 2025
Navigating Challenges: Immune Cells vs. Cancer Cells
In the ever-evolving world of cancer treatment, immuno-oncology (IO) continues to stand at the forefront of innovation. With recent FDA approvals for TIL therapies and bispecific antibodies, and new developments in CAR-T technologies, the field is rapidly expanding into combination-based strategies that integrate with standard care. Researchers are also exploring how to overcome challenges posed by the tumor microenvironment and immune cell exhaustion to increase therapeutic success rates.
4 Mar 2025
Beyond the Lab: The Evolving Role of CROs
14 Feb 2025
The Competitive Edge: How CROs Stay Ahead in Drug Discovery
Reach and audience
Public platform figures. Ratings count people who left a rating, not total listeners.
Spotify
5.0 / 5
2 ratings
Podcast Authority Score: 10 / 100
A composite of feed quality, social presence, YouTube performance and engagement. Read the methodology.
Quality
19
Social presence
0
YouTube
0
Engagement
0
Host of CrownCast?
Claim your podcast to manage its listing and keep your show details accurate.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show Podcast research with Pod Engine
